Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Asset Writedowns and Impairment (2020 - 2024)

Arcadia Biosciences filings provide 5 years of Asset Writedowns and Impairment readings, the most recent being $154000.0 for Q3 2024.

  • On a quarterly basis, Asset Writedowns and Impairment fell 38.89% to $154000.0 in Q3 2024 year-over-year; TTM through Dec 2025 was $154000.0, a 0.0% change, with the full-year FY2024 number at $154000.0, up 670.0% from a year prior.
  • Asset Writedowns and Impairment hit $154000.0 in Q3 2024 for Arcadia Biosciences, up from -$424000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $2.5 million in Q4 2022 to a low of -$424000.0 in Q4 2023.
  • Median Asset Writedowns and Impairment over the past 5 years was $252000.0 (2023), compared with a mean of $686352.9.
  • The widest YoY moves for Asset Writedowns and Impairment: up 1580.0% in 2023, down 117.18% in 2023.
  • Arcadia Biosciences' Asset Writedowns and Impairment stood at $1.2 million in 2020, then soared by 90.08% to $2.3 million in 2021, then rose by 8.2% to $2.5 million in 2022, then plummeted by 117.18% to -$424000.0 in 2023, then surged by 136.32% to $154000.0 in 2024.
  • The last three reported values for Asset Writedowns and Impairment were $154000.0 (Q3 2024), -$424000.0 (Q4 2023), and $252000.0 (Q3 2023) per Business Quant data.